RxDoctor Payments Data

Henry Boler, MD

Internal Medicine · Tupelo, MSNPI 1578926663

Payments from drug & device makers

$7,132in general payments, 2019–2025

Across 241 payments — averaging $29.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • United Imaging Healthcare North America LLC$863
  • Boehringer Ingelheim$617
  • Pfizer$553
  • Merck$525
  • AstraZeneca$442
  • Penumbra, Inc.$435
  • plus $4K from 28 others

What the payments were for

  • Travel & lodging$86812%
  • Food & beverage$6,26488%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,132 in reported general payments places this provider in the 90th percentile of 846 internal medicine providers in Mississippi.

See all internal medicine providers in Mississippi

Medicare billing

Part B allowed, 2024
$700,134
Medicare patients
3,358
Services billed
19,265

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan100$79,719
JardianceEmpagliflozin85$60,426
EliquisApixaban41$40,768
FarxigaDapagliflozin Propanediol33$30,802
XareltoRivaroxaban16$12,967
BrilintaTicagrelor17$7,428
Repatha SyringeEvolocumab12$6,627
Digoxin21$2,029
Metoprolol Succinate222$1,806
Propafenone Hcl41$1,064
Rosuvastatin Calcium107$887
Isosorbide Mononitrate ErIsosorbide Mononitrate117$721
Ezetimibe64$649
Atorvastatin Calcium109$474
Carvedilol151$462

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$265$79,719100 claims
Boehringer IngelheimJardiance$617$60,42685 claims
PfizerEliquis$553$40,76841 claims
AstraZenecaFarxiga, Brilinta$442$38,23050 claims
Johnson & JohnsonXarelto$187$12,96716 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 846 internal medicine providers in Mississippi.

Other internal medicine in Tupelo

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →